/

Società

No

Non verificato

Norgine B.V.

Di cosa scriviamo

FarmaceuticaFitnessFondi di investimentoMedicina - VarieSalute

2 comunicati stampa

Guarda tutti i comunicati

Press Release cover image

29/04/2026

Salute

Fitness

Medicina - Varie

Scienza

Norgine announces European Commission Marketing Authorisation for XOLREMDI® (mavorixafor), the first authorised treatment for patients with WHIM syndrome in the European Union

Fonte

Emittente

1.00

0

Press Release cover image

05/03/2026

Salute

Fitness

Finanza

Risparmio/Affari personali

Fondi di investimento

Medicina - Varie

Norgine announces £23 million new investment as part of more than £50 million committed to expanding medicines manufacturing in Wales

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0